HR Execs on the Move

CanaFarma Corporation

www.canafarmacorp.com

 
Canafarma Corp. has the technology and products that can be offered to the market. Successful experience with chewing gum Yooforic, the flagship product of the company — this confirms! Our product is in demand, so right now we are ready to expand the range, offer new products and enter a new level of development of both production facilities and the distribution network.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Verim Research

Verim Research is a Hood River, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Texas Visiting Nurse Service

Texas Visiting Nurse Service is a Harlingen, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Veterinary Care

Your vision. Our resources. Together we can build a bright future for your practice and the veterinary industry as a whole.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

Dudnyk Healthcare Group

Dudnyk Healthcare Group is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.